ROCKVILLE, Md., Nov. 19, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, today announced it is hosting a Microbiome Clinical Program Seminar on Thursday, December 10, 2015 from 9:00 a.m. – 11:30 a.m. EST in New York City.
Clinical updates will be provided on Synthetic Biologics' gut microbiome candidates – SYN-010 and SYN-004:
SYN-010 – Treatment of irritable bowel syndrome with constipation (IBS-C)
Topics: First and second Phase 2 clinical trials
- Mark Pimentel, MD, FRCP(C), Director, GI Motility Program, Professor of Medicine, Cedars-Sinai, Los Angeles, CA
- Marianela de la Portilla, MD, Principal Investigator, Genoma Research Group, Miami, FL
SYN-004 – Prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD)
Topics: Phase 1a and 1b, first and second Phase 2a and Phase 2b clinical trials
- Professor Mark H. Wilcox, MD, FRCPath, Consultant / Head of Microbiology, Leeds Teaching Hospitals NHS Trust, Professor of Medical Microbiology, University of Leeds, Lead on C. difficile Infection, Public Health England
- Eric Sicard, MD, Principal Investigator, Algorithme Pharma, Quebec, Canada
Space is limited, and attendance is by invitation only. A live webcast will be available at www.syntheticbiologics.com, and an archived replay will be available following the event. For further information, please contact Vincent I. Perrone, Manager, Corporate Communication, (301) 417-4364, SYNInvestorDay@syntheticbiologics.com.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon Corporation (NYSE: XON), a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.